CH-01 is a Hypoxia-Activated Prodrug That Sensitizes Cells to Hypoxia/Reoxygenation Through Inhibition of Chk1 and Aurora A

[Image: see text] The increased resistance of hypoxic cells to all forms of cancer therapy presents a major barrier to the successful treatment of most solid tumors. Inhibition of the essential kinase Checkpoint kinase 1 (Chk1) has been described as a promising cancer therapy for tumors with high le...

Descripción completa

Detalles Bibliográficos
Autores principales: Cazares-Körner, Cindy, Pires, Isabel M., Swallow, I. Diane, Grayer, Samuel C., O’Connor, Liam J., Olcina, Monica M., Christlieb, Martin, Conway, Stuart J., Hammond, Ester M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2013
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3719478/
https://www.ncbi.nlm.nih.gov/pubmed/23597309
http://dx.doi.org/10.1021/cb4001537

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3719478/
https://www.ncbi.nlm.nih.gov/pubmed/23597309
http://dx.doi.org/10.1021/cb4001537

Ejemplares similares